SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine

Sebastian Marschner1,2, Stefanie Corradini1, Josefine Rauch1

  • 1Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Abstract

Insights

A German Radiation Oncology department implemented COVID-19 prevention measures and PCR testing for asymptomatic cancer patients. Only 0.72% of patients tested positive, demonstrating effective screening to protect vulnerable populations.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Public Health

Background:

  • The COVID-19 pandemic presents a significant global health challenge.
  • Lack of vaccines and treatments necessitates robust prevention and testing strategies.
  • Cancer patients represent a vulnerable population requiring specific protective measures.

Purpose of the Study:

  • To evaluate the implementation and effectiveness of COVID-19 prevention measures in a German Radiation Oncology department.
  • To report on the initial results of Polymerase Chain Reaction (PCR) testing for asymptomatic cancer patients.
  • To assess the prevalence of SARS-CoV-2 in this specific patient cohort.

Main Methods:

  • Implemented pandemic-adapted hygiene protocols, including mask mandates and physical distancing.
  • Instituted a visiting ban and utilized telephone follow-ups for clinical management.
  • Conducted pre-treatment nasopharyngeal swab PCR testing for all asymptomatic cancer patients.
  • Developed patient educational materials on COVID-19 symptoms and prevention.

Main Results:

  • Implemented measures were well-accepted by both patients and staff.
  • PCR testing identified 1 out of 139 asymptomatic cancer patients (0.72%) as positive for SARS-CoV-2.
  • No staff members tested positive for SARS-CoV-2 during the study period.
  • Treatment initiation was deferred for the single PCR-positive patient.

Conclusions:

  • The department demonstrated preparedness for the COVID-19 crisis through implemented measures.
  • Initial PCR screening effectively identified asymptomatic COVID-19 cases, safeguarding other patients and staff.
  • The observed SARS-CoV-2 prevalence aligns with findings from comparable studies.
  • Regular PCR testing for all patients and staff is desirable but currently limited by testing capacity.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
568
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.4K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.7K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
861